BMS-986094 (INX-08189) is a guanosine nucleotide analogue prodrug which was developed to treat hepatitis C virus (HCV). However, BMS-986094 was discontinued in Phase III clinical trials with 1 death and 8 people hospitalised with significantly reduced left ventricular ejection fraction (LVEF). Cardiotoxic effects were observed in 14 out of the 34 patients with left ventricular dysfunction, with ST depressions, T-wave inversions or loss of T-wave amplitude.
In this poster, we focus on:
investigating the mechanism behind the cardiotoxicity of BMS-986094
the use of MEA and human iPSC-derived cardiomyocytes in long term incubations with BMS-986094
Read our poster to learn more about our research!
Sounds interesting? Enter your details below to continue reading…
Join our community
Discover the exclusive benefits on offer if you join our community.